Has Lowell Schmeltz, MD received payments from drug or device companies?

Yes. Drug and device makers reported $2,268,634 in general payments to Lowell Schmeltz, MD across 2,602 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Lowell Schmeltz, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Lowell Schmeltz, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Lowell Schmeltz, MD

Endocrinology, Diabetes & Metabolism · Farmington Hills, MINPI 1538112917

Payments from drug & device makers

$2,268,634in general payments, 2019–2025

Across 2,602 payments — averaging $871.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$643K
AbbVie$556K
Abbott$253K
Novo Nordisk$249K
Sanofi-aventis U.S. LLC$110K
Siemens Medical Solutions USA, Inc.$108K
plus $350K from 52 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	1,124	$643,192
AbbVie(2 entities)	120	$555,561
Abbott	211	$252,797
Novo Nordisk	345	$249,313
Sanofi-aventis U.S. LLC	132	$109,571
Siemens Medical Solutions USA, Inc.	4	$108,013
Roche Diagnostics Operations, Inc.	33	$83,210
Dexcom, Inc.	79	$59,633
Boehringer Ingelheim	54	$56,580
Sanofi US Services Inc.	8	$45,763
Sanofi	12	$38,394
Tandem Diabetes Care, Inc.	15	$17,847
Bayer	22	$17,414
Merck	42	$9,980
Xeris Pharmaceuticals, Inc.	35	$8,692
Insulet Corporation	13	$3,877
Vistapharm, Inc.	3	$2,750
Amgen(2 entities)	102	$1,417
AstraZeneca(2 entities)	33	$490
Mannkind Corporation	32	$467
Corcept Therapeutics	20	$447
Amneal Pharmaceuticals LLC	20	$314
BD	3	$287
Pfizer	11	$189
Ascendis Pharma Endocrinology Inc	7	$164
Ascensia Diabetes Care US Inc.	12	$158
Radius Health, Inc.	8	$156
Alvogen Inc	8	$153
Neurocrine Biosciences, Inc.	5	$128
Amryt Pharma Holdings Ltd	8	$128
Madrigal Pharmaceuticals	4	$126
Amphastar Pharmaceuticals, Inc.	6	$121
Recordati_rare_diseases_inc.	6	$116
Lifescan, Inc.	7	$110
Nevro Corp.	3	$106
Medtronic(2 entities)	5	$95
Antares Pharma, Inc.	5	$76
Shire North American Group Inc	5	$71
Johnson & Johnson	4	$56
Verity Pharmaceuticals Inc.	3	$54
Ultragenyx Pharmaceutical Inc.	3	$53
Ipsen Biopharmaceuticals, Inc	3	$51
Kyowa Kirin, Inc.	2	$49
Cequr Corporation	2	$49
Zealand Pharma US, Inc.	2	$42
Sequel Med Tech, LLC	2	$41
Chiesi USA, Inc.	2	$41
IBSA Pharma Inc.	3	$39
EUSA Pharma (US) LLC	2	$35
Tolmar, Inc.	2	$35
Takeda Pharmaceuticals U.S.A., Inc.	1	$33
Novartis	2	$32
Valeritas, Inc.	2	$31
Esperion Therapeutics, Inc.	1	$22
Companion Medical, Inc.	1	$21
GSK	1	$18
Gilead	1	$16
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	1	$13

How this compares

$2,268,634 in reported general payments places this provider in the 95th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.

See all endocrinology, diabetes & metabolism providers in Michigan →

Medicare billing

Part B allowed, 2024

$170,090

Medicare patients

649

Services billed

2,958

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Farmington Hills

Gary EdelsonFarmington Hills$503K
Tobias ElseAnn Arbor$3.5M
Elif OralAnn Arbor$2.9M
Jamal HammoudFlint$2.6M
George GrunbergerBloomfield Hills$1.9M
Richard AuchusAnn Arbor$1.3M
Ariel BarkanAnn Arbor$553K
Michael BrennanSaint Clair Shores$433K
Abdulsalam Al KassabRochester Hills$351K
Arti BhanDetroit$298K

See the full list for Michigan →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →